Editor's Note: Green and red arrows refer to intraday stock price movement.



) --


Becton Dickinson

(BDX) - Get Becton, Dickinson and Company Report

upgraded at Goldman to Buy. Emerging markets should drive growth over the coming quarters.


(BMY) - Get Bristol-Myers Squibb Company Report

downgraded at Goldman to Neutral. $77 price target. JNJ looks better at current levels.

Dick's Sporting Goods

(DKS) - Get Dick's Sporting Goods, Inc. Report

upgraded at Goldman to Buy. $49 price target. Company should continue to deliver solid organic growth.


(GNC) - Get GNC Holdings, Inc. Class A Report

rated new Neutral at Goldman. Valuation call, based on a $22 price target.


(GNC) - Get GNC Holdings, Inc. Class A Report

rated new Overweight at Morgan Stanley. $23 price target. Company is a clear market leader and can deliver consistent, double-digit annual earnings growth.



downgraded at Goldman to Neutral, Goldman Sachs said. Company lacks near-term catalysts.


(IDA) - Get IDACORP, Inc. Report

downgraded at Keybanc from Buy to Hold. Valuation call, as the stock has nearly doubled the performance of its peers year-to-date.

TheStreet Recommends

Johnson & Johnson

(JNJ) - Get Johnson & Johnson (JNJ) Report

upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Product pipeline could drive accelerating earnings growth. $77 price target.


(NTAP) - Get NetApp, Inc. (NTAP) Report

upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $70 price target. Company deserves a higher multiple.

Research in Motion

( RIMM) downgraded at Societe Generale to Hold. Reception has been mixed for new products.

Rosetta Resources

(ROSE) - Get Rosehill Resources Inc. Class A Report

upgraded at Citi to Buy from Hold as Alberta Bakken catalyst comes sooner than expected, Citigroup said. Price target jumped to $60 from $44.



upgraded at Maxim from Hold to Buy, Maxim Group said. $67 price target. Company is cutting costs and can accelerate growth.



estimates, target raised at Goldman. Shares of ROVI now seen reaching $60, according to Goldman Sachs. Estimates also increased, given new customer wins. Neutral rating.



rated new Buy at ThinkEquity. $94 price target. Company is leveraged to several growth drivers.


(SYK) - Get Stryker Corporation Report

upgraded at Goldman to Buy. Orthopedic business should drive near-term growth.

Thomas & Betts

( TNB) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $68 price target. Estimates also boosted, as the company is seeing better end-market demand.

End of report.

This article was written by a staff member of TheStreet.